Locus-Specific and Stable DNA Demethylation at the H19/ IGF2 ICR1 by Epigenome Editing Using a dCas9-SunTag System and the Catalytic Domain of TET1

Genes (Basel). 2024 Jan 8;15(1):80. doi: 10.3390/genes15010080.

Abstract

DNA methylation is critically involved in the regulation of chromatin states and cell-type-specific gene expression. The exclusive expression of imprinted genes from either the maternal or the paternal allele is regulated by allele-specific DNA methylation at imprinting control regions (ICRs). Aberrant DNA hyper- or hypomethylation at the ICR1 of the H19/IGF2 imprinting locus is characteristic for the imprinting disorders Beckwith-Wiedemann syndrome (BWS) and Silver-Russell syndrome (SRS), respectively. In this paper, we performed epigenome editing to induce targeted DNA demethylation at ICR1 in HEK293 cells using dCas9-SunTag and the catalytic domain of TET1. 5-methylcytosine (5mC) levels at the target locus were reduced up to 90% and, 27 days after transient transfection, >60% demethylation was still observed. Consistent with the stable demethylation of CTCF-binding sites within the ICR1, the occupancy of the DNA methylation-sensitive insulator CTCF protein increased by >2-fold throughout the 27 days. Additionally, the H19 expression was increased by 2-fold stably, while IGF2 was repressed though only transiently. Our data illustrate the ability of epigenome editing to implement long-term changes in DNA methylation at imprinting control regions after a single transient treatment, potentially paving the way for therapeutic epigenome editing approaches in the treatment of imprinting disorders.

Keywords: DNA demethylation; ICR; SunTag; TET1; dCas9; epigenome editing; imprinting.

MeSH terms

  • Alleles
  • Catalytic Domain
  • DNA Demethylation*
  • Epigenome
  • HEK293 Cells
  • Humans
  • Imprinting Disorders*
  • Insulin-Like Growth Factor II / genetics
  • Mixed Function Oxygenases / genetics
  • Proto-Oncogene Proteins

Substances

  • TET1 protein, human
  • Mixed Function Oxygenases
  • Proto-Oncogene Proteins
  • IGF2 protein, human
  • Insulin-Like Growth Factor II

Grants and funding

This work was partially funded by the DFG (project JE 252/42-1) and the BW Foundation (Epigenetics program, project ID09).